/

LENSAR, Inc.

LNSR US

LNSR USLENSAR, Inc.

United States Composite

3.23

USD

+0.16

(+5.11%)

-1.29EPS Dil.

-2.46P/E

36.55MMarket Cap

Next Earnings

May 13

Held by Insiders

17.81%

Held by Institutions

41.98%

Short % of Float

0.46%

YTD Yield

18.27%

3Y Yield

-52.97%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

20.00%

Net Income, GAAP

-NaN%

30.00%

Free Cash Flow

-NaN%

33.33%

Total Cash Common Dividend

- -

Total Equity

-NaN%

-21.43%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.56

-0.47

-0.65

-0.41

-2.09

2022

-0.67

-0.39

-0.24

-1.96

2023

-0.40

-0.81

0.23

-0.35

-1.31

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Nicholas T. Curtis
Full Time Employees: 130
Sector: Healthcare
Industry: Medical Devices
Address: 2800 Discovery Drive Orlando FL United States 32826
IPO Date: Oct 2, 2020
Website: www.lensar.com
Business: LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Company News

Tipranks
2 months ago
A New Cause for Concern: Lensar Inc Adds a New Share Price & Shareholder Rights Risk

Company Description

CEO: Mr. Nicholas T. Curtis
Full Time Employees: 130
Sector: Healthcare
Industry: Medical Devices
Address: 2800 Discovery Drive Orlando FL United States 32826
IPO Date: Oct 2, 2020
Website: www.lensar.com
Business: LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.